Agonist-selective signaling of G protein-coupled receptor: mechanisms and implications
about
Non-Coding RNAs Regulating Morphine Function: With Emphasis on the In vivo and In vitro Functions of miR-190G protein-coupled receptors in the hypothalamic paraventricular and supraoptic nuclei--serpentine gateways to neuroendocrine homeostasisTargeting G protein coupled receptor-related pathways as emerging molecular therapiesDevelopment and evaluation of small peptidomimetic ligands to protease-activated receptor-2 (PAR2) through the use of lipid tethering[EXPRESS] Peripheral inflammatory injury alters the relative abundance of Gα subunits in the dorsal horn of the spinal cord and in the rostral ventromedial medulla of male rats.Yin Yang 1 phosphorylation contributes to the differential effects of mu-opioid receptor agonists on microRNA-190 expression.Modulations of NeuroD activity contribute to the differential effects of morphine and fentanyl on dendritic spine stability.Lanthanide labeling of a potent protease activated receptor-2 agonist for time-resolved fluorescence analysis.Hyaluronic acid induces activation of the κ-opioid receptor.Chemokine-like receptor 1 (CMKLR1) and chemokine (C-C motif) receptor-like 2 (CCRL2); two multifunctional receptors with unusual propertiesMechanism of down-regulation of RNA polymerase III-transcribed non-coding RNA genes in macrophages by Leishmania.Modulating micro-opioid receptor phosphorylation switches agonist-dependent signaling as reflected in PKCepsilon activation and dendritic spine stability.Cellular signalling of non-synonymous single-nucleotide polymorphisms of the human μ-opioid receptor (OPRM1)Biophysical characterization of G-protein coupled receptor-peptide ligand binding.The protease-activated receptor-2-specific agonists 2-aminothiazol-4-yl-LIGRL-NH2 and 6-aminonicotinyl-LIGRL-NH2 stimulate multiple signaling pathways to induce physiological responses in vitro and in vivoWheel running reduces high-fat diet intake, preference and mu-opioid agonist stimulated intake.In Silico Modeling of Novel Drug Ligands for Treatment of Concussion Associated Tauopathy.Cholesterol level influences opioid signaling in cell models and analgesia in mice and humans.In vivo visualization of delta opioid receptors upon physiological activation uncovers a distinct internalization profileG-protein βγ subunits in vasorelaxing and anti-endothelinergic effects of calcitonin gene-related peptideδ-Opioid mechanisms for ADL5747 and ADL5859 effects in mice: analgesia, locomotion, and receptor internalization.Delta opioid receptor analgesia: recent contributions from pharmacology and molecular approaches.3-(1H-indol-3-yl)-2-[3-(4-nitrophenyl)ureido]propanamide enantiomers with human formyl-peptide receptor agonist activity: molecular modeling of chiral recognition by FPR2Opioid doses required for pain management in lung cancer patients with different cholesterol levels: negative correlation between opioid doses and cholesterol levelsPosttranslation modification of G protein-coupled receptor in relationship to biased agonism.Endocytic profiles of δ-opioid receptor ligands determine the duration of rapid but not sustained cAMP responses.Epigenetics of µ-opioid receptors: intersection with HIV-1 infection of the central nervous system.Signal protein-derived peptides as functional probes and regulators of intracellular signaling.Consensus 3D model of μ-opioid receptor ligand efficacy based on a quantitative Conformationally Sampled Pharmacophore.Potentiation of Morphine-Induced Antinociception by Propranolol: The Involvement of Dopamine and GABA Systems.
P2860
Q21131252-08318DA3-6910-4167-A283-3647679A4D70Q24633335-872BFADD-F08A-4BEF-9888-F1277137239CQ26829964-F356D20D-5569-4463-B403-3A3F948E6158Q28539692-AF17EC15-5A8F-4AB0-8CFF-1CB460404D7FQ33840507-A189204A-E0C1-4BE5-9449-591112ED978FQ33991318-54BF1A78-9982-4992-8CFE-36D681E24C06Q34033565-702ECC54-C86F-40A3-BB2F-AF768B8C4407Q34300774-8A675A15-4E2C-4C20-A984-7467AA07EB1EQ34576652-E9C3433E-F26A-4B90-9318-DD6B2209BA2CQ34629210-8FA318C1-075E-4FAE-99CD-9E4552FE27ACQ34675826-3F707EE7-A3D1-44A3-9913-6A02BFDCF74CQ34752640-6DBB6FBF-FFC1-4893-9D5E-A8A0CB9C355CQ34939590-A7D2C58C-CFAF-411B-AE09-A3FBBD56AA01Q34987728-540276C5-B77D-4586-A1EC-910FB1E03EF6Q34998283-197DC36F-E193-4674-96D7-639DE81F2B7CQ35238013-EFB81C65-FDE8-4D00-B479-3F6C0EC6F6B7Q35934088-B8B4BD04-87E9-409A-AEE1-95C867D6135DQ35958466-7486C326-9CA1-4E27-AE16-F62D00EF9B06Q36020861-7D58E0E7-3FA4-4FED-BB38-E698B9ED8A10Q36153281-9D90007A-A134-407F-BCE9-D2C782722F0DQ36174184-C8286940-8E3B-4C20-8075-10A55A2D2DE5Q36438816-AEC055C2-512B-4CF2-B45E-8CCE140947E9Q36557131-F7502B00-9129-4E31-A5BA-B03F457D0523Q36662387-1E50E96F-5F2E-43AA-AA01-E918D20602E0Q37322612-458E065F-52BA-4A5A-A15F-9FB8BC70B512Q37405423-5F565C94-41EC-4DF0-B492-CB57151339E9Q37950301-26CC6C18-222F-4413-9DAA-3C2866D469B9Q37982071-692E61F0-F20E-4B5D-A1FE-FB29EB3F7102Q41835961-2846F918-7F4B-43D5-8CFF-9FF079378B57Q46364592-22FF9233-3243-4BC2-A7DF-4324F7C887B5
P2860
Agonist-selective signaling of G protein-coupled receptor: mechanisms and implications
description
2010 nî lūn-bûn
@nan
2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Agonist-selective signaling of G protein-coupled receptor: mechanisms and implications
@ast
Agonist-selective signaling of G protein-coupled receptor: mechanisms and implications
@en
type
label
Agonist-selective signaling of G protein-coupled receptor: mechanisms and implications
@ast
Agonist-selective signaling of G protein-coupled receptor: mechanisms and implications
@en
prefLabel
Agonist-selective signaling of G protein-coupled receptor: mechanisms and implications
@ast
Agonist-selective signaling of G protein-coupled receptor: mechanisms and implications
@en
P2860
P356
P1433
P1476
Agonist-selective signaling of G protein-coupled receptor: mechanisms and implications
@en
P2093
Horace H Loh
P2860
P304
P356
10.1002/IUB.293
P577
2010-02-01T00:00:00Z